Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 6, 2024
Reporting Period: Single event date (February 6, 2024)
The filing addresses a regulatory compliance matter regarding the Company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to a notification of regulatory compliance status.
Material Changes
- Regulatory Status: The Company received written notification from the NASDAQ Stock Market Listing Qualifications Staff confirming it has regained compliance with the $1.00 minimum closing bid price requirement (NASDAQ Listing Rule 5550(a)(2)).
- Outcome: The matter regarding the minimum bid price deficiency is now closed.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the regained compliance but does not provide additional forward-looking guidance or management commentary within the text of the 8-K itself.
Risks and Contingencies: No new risks or contingencies are disclosed in this specific filing. The resolution of the minimum bid price issue removes the immediate risk of delisting associated with that specific rule.
Investor Verification Checklist
- Verify the current trading price of PCSA on the Nasdaq Capital Market to ensure continued compliance with the $1.00 minimum bid price rule.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the Company's capital structure or stock price history leading to this compliance.
- Confirm the Company's ongoing financial health through its most recent 10-K or 10-Q filings, as this 8-K contains no financial data.